JP2022544057A - ニテニン類似体化合物ならびに慢性および急性疼痛の治療におけるそれらの使用 - Google Patents

ニテニン類似体化合物ならびに慢性および急性疼痛の治療におけるそれらの使用 Download PDF

Info

Publication number
JP2022544057A
JP2022544057A JP2022506029A JP2022506029A JP2022544057A JP 2022544057 A JP2022544057 A JP 2022544057A JP 2022506029 A JP2022506029 A JP 2022506029A JP 2022506029 A JP2022506029 A JP 2022506029A JP 2022544057 A JP2022544057 A JP 2022544057A
Authority
JP
Japan
Prior art keywords
pain
compound
alkyl
nitenin
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022506029A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022544057A5 (https=
Inventor
サントス バルタザール デ リマ，ペドロ アフォンソ ドス
ドス サントス，ベアトリス シュワルツ
アブレウ，アナ ロサ マソ
バストス，アンドレ エマヌエル ピニェイロ
ゴメス，ルイ
デ ソウザ，マリサ イサベル ロペス
セラーン，ジョアナ マリア モンテイロ
リノ，シルヴィア パトリシア ペナ
シルヴェイラ マキシモ，パトリシア イサベル ダ
フェレイラ，ルイーザ マリア ピント
セリオ ブランコ，パウラ クリスチナ デ
モウラン，エンリケ ソヴェラ
サビノ，ヴァネッサ アレキサンドラ ロサド
トン，ミン ヒム
アラン クロード－トレンブル，ローラン
ダ コスタ ロレンソ，アナ マリア フェレイラ
モンドラガオ，ミゲル アンジェロ セガオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sea4us Biotecnologia e Recursos Marinhos Ltda
Original Assignee
Sea4us Biotecnologia e Recursos Marinhos Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sea4us Biotecnologia e Recursos Marinhos Ltda filed Critical Sea4us Biotecnologia e Recursos Marinhos Ltda
Publication of JP2022544057A publication Critical patent/JP2022544057A/ja
Publication of JP2022544057A5 publication Critical patent/JP2022544057A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/28—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/36—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2022506029A 2019-07-31 2020-07-22 ニテニン類似体化合物ならびに慢性および急性疼痛の治療におけるそれらの使用 Pending JP2022544057A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PT11568519 2019-07-31
PT115685 2019-07-31
PCT/IB2020/056915 WO2021019373A1 (en) 2019-07-31 2020-07-22 Nitenin analogue compounds and their use in the treatment of chronic and acute pain

Publications (2)

Publication Number Publication Date
JP2022544057A true JP2022544057A (ja) 2022-10-17
JP2022544057A5 JP2022544057A5 (https=) 2024-02-20

Family

ID=72240450

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022506029A Pending JP2022544057A (ja) 2019-07-31 2020-07-22 ニテニン類似体化合物ならびに慢性および急性疼痛の治療におけるそれらの使用

Country Status (10)

Country Link
US (1) US12336977B2 (https=)
EP (1) EP4003984A1 (https=)
JP (1) JP2022544057A (https=)
CN (1) CN114616230A (https=)
AU (1) AU2020320115A1 (https=)
CA (1) CA3149175A1 (https=)
IL (1) IL290192A (https=)
MX (1) MX2022001186A (https=)
WO (1) WO2021019373A1 (https=)
ZA (1) ZA202201154B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4003984A1 (en) 2019-07-31 2022-06-01 Sea4Us - Biotecnologia e Recursos Marinhos, Lda. Nitenin analogue compounds and their use in the treatment of chronic and acute pain
CN116115739B (zh) * 2022-12-29 2024-01-09 天津市肿瘤医院（天津医科大学肿瘤医院） 胃动素及其受体激动剂的应用
WO2026013449A2 (en) * 2024-07-11 2026-01-15 Sea4Us - Biotecnologia E Recursos Marinhos, Sa Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150284405A1 (en) * 2014-04-04 2015-10-08 Pfizer Inc. Bicyclic-Fused Heteroaryl or Aryl Compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7375136B2 (en) 2001-03-08 2008-05-20 Emory University pH-dependent NMDA receptor antagonists
GB0305149D0 (en) * 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Compounds for the treatment of pain
WO2007009462A2 (en) 2005-07-15 2007-01-25 Region Hovedstaden V/Glostrup Hospital Treatment of migraine and headaches
ES2345527B1 (es) 2008-10-08 2011-09-08 Hospital Clinic I Provincial De Barcelona Sustancias bloqueadoras de los canales kv 1.3 para el tratamiento de enfermedades asociadas a hiperplasia de la intima.
KR101939401B1 (ko) 2011-11-10 2019-01-16 가천대학교 산학협력단 단핵식세포계 세포의 ａｇｅ-알부민 합성 또는 분비 저해제를 유효성분으로 포함하는 허혈성 심장질환 예방 또는 치료용 조성물
CN106537149A (zh) * 2014-04-01 2017-03-22 宝洁公司 用于筛选色氨酸通道的方法
CN106146530A (zh) * 2015-04-14 2016-11-23 中国科学院生态环境研究中心 一种合成cephalosporolides E,F,H,I的新方法
EP4003984A1 (en) 2019-07-31 2022-06-01 Sea4Us - Biotecnologia e Recursos Marinhos, Lda. Nitenin analogue compounds and their use in the treatment of chronic and acute pain

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150284405A1 (en) * 2014-04-04 2015-10-08 Pfizer Inc. Bicyclic-Fused Heteroaryl or Aryl Compounds

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BIOORGANIC CHEMISTRY, vol. 86, JPN6024013616, 31 May 2019 (2019-05-31), pages 665 - 673, ISSN: 0005485643 *
CHEMISTRY A EUROPEAN JOURNAL, vol. 10, JPN6024013617, 2004, pages 4584 - 4593, ISSN: 0005485641 *
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, vol. 2019, JPN6024013615, 3 March 2019 (2019-03-03), pages 1 - 8, ISSN: 0005485642 *
TETRAHEDRON, vol. 27, JPN6024013614, 1971, pages 3909 - 3917, ISSN: 0005485640 *
THE JOURNAL OF ANTIBIOTICS, vol. 55, no. 1, JPN6024050997, 2002, pages 104 - 106, ISSN: 0005692584 *

Also Published As

Publication number Publication date
CA3149175A1 (en) 2021-02-04
ZA202201154B (en) 2024-02-28
IL290192A (en) 2022-03-01
CN114616230A (zh) 2022-06-10
AU2020320115A1 (en) 2022-02-24
WO2021019373A4 (en) 2021-03-25
US12336977B2 (en) 2025-06-24
MX2022001186A (es) 2022-05-11
WO2021019373A1 (en) 2021-02-04
EP4003984A1 (en) 2022-06-01
US20220288017A1 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
ES2354417T3 (es) Nuevo uso de una clase de compuestos peptídicos para tratar alodinia u otros tipos diferentes de dolor crónico o fantasma.
JP2022544057A (ja) ニテニン類似体化合物ならびに慢性および急性疼痛の治療におけるそれらの使用
JP2025163030A (ja) 慢性および急性疼痛の治療における使用のためのｋｖ１．３アンタゴニスト
AU2002257680A1 (en) Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain
Yamada Therapeutic potential of positive AMPA receptor modulators in the treatment of neurological disease
US11298337B2 (en) Parthenolide and its derivative for use in the treatment of axonal damage
Yamamoto et al. N-and L-type calcium channels blocker cilnidipine ameliorates neuropathic pain
HK40076622A (en) Nitenin analogue compounds and their use in the treatment of chronic and acute pain
AU2020322218B2 (en) Kv1.3 antagonists for use in the treatment of chronic and acute pain
Donkor et al. Neuroprotective effect of Sigma-2 modulator CT2074 in a mouse model of ocular hypertension
KR101100002B1 (ko) 신경병증성 및 정신성 만성통증증후군의 치료 목적의약제의 제조를 위한 피리딘-2-일-메틸아민 유도체의 용도
AU2019276000B2 (en) Safinamide for treating myotonia
US7834040B2 (en) Isoxazolic derivative to relieve neuropathic pain
US20110223166A1 (en) Methods for Preventing Pressure-Induced Apoptotic Neural-Cell Death
AU2006236018B2 (en) Methods for preventing pressure induced apoptotic neural cell death
HUT65880A (en) Process for preparation of ophtalmological medicaments containing pyridine derivatives usefules for treatment of ocular hypertension
Ondo Overview of the Medical Treatments of Hyperkinetic Disorders
WO2002011739A1 (en) Methods for preventing pressure induced apoptotic neural cell death
AU2001278306A1 (en) Methods for preventing pressure induced apoptotic neural cell death
MX2012015090A (es) Uso de 1h-quinazolina-2,4-dionas.

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240209

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240416

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240716

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250314

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250616

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260305